Coldnewfie, Kelsee & RVX longs:

Thank you all for your enthusiasim and confidence displayed these past few weeks as RVX moves into this critical trial.

IMHO DM & corp are well aware of the 'trials ahead' in gaining blockbuster scientific and market acceptance as noted in the following excerpt lifted from the September 29, 2015 Corporate update as posted by imtesty:

SLIDE 93

(RVX-208 Additional Clinical Plan Potentials)

I’m glad that Ewelina had to pronounce all those words in the potential indications that we can go into in complement, but there are a lot of directions here for us. And this has been very well planned, because we knew that we were going to have about a three-year gap in data while the BETonMACE trial is in full function. So we’ve designed it so that there will be a lot of value and inflection points during that three-year period.

Chronic Kidney Disease is a huge potential for us. I think you can understand from Kam’s excitement that we really have something there, and we will build towards that.

Peripheral arterial disease. That’s very much a natural, especially with all the anti-inflammatory components going on.

Alzheimer’s. We’ve talked about Alzheimer’s for a while. We were waiting for some NIH funding, which is always in the process. But at the most recent international Alzheimer’s conference, the big study subject, the big breakthrough was the relationship to complement in Alzheimer’s. So we’re very excited about moving forward with that potential as well.

And then of course the orphan indications. Which orphan drugs seem to be very popular with pharma these days? Eight ten years ago everybody switched into oncology, now it’s orphan indications. So to be able to enter those indications with RVX-208 already as a Phase II B drug is fantastic. And to back-up molecules for that program for other indications is even better.

SLIDE 94

(Early revenue opportunities include regional licensing deals and orphan indications)

And we will continue with some of the plans that we’ve talked about over the past. The orphan indications, as we started rolling that out yesterday.

We will continue with regional deals potential as well. We are in discussion. We like regional components. We try to stay away from the main countries that would get you your highest value in global deals. But there are a lot of places where we can utilize regional pricing for bringing in revenues at a lot earlier point.

We all know now that Resverlogix is more than a one-trick pony. Sending another horse out of the barn will temper the investment risk of possible Betonmace failure. Market value will build with each indication and deal. Building a herd takes time & DM & Co are doing a remarkable job of it. RVX has declared itself a Pioneer and been branded as such by the market. The "arrows in the back" syndrome embraced by the naysayers weigh's heavy on the market value. The Indians will soon fade into the hills.

Long and Strong-

Chicagoest